LFCR

Lifecore Biomedical, Inc.

6.43 USD

Last updated Oct 13, 01:03 UTC

Yesterday HIGH

$6.46

Yesterday LOW

$6.42

52w HIGH

$8.98

52w LOW

$3.62

EPS

-0.19

PE

-33.84

Next Earnings

Nov 5, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Lifecore Biomedical, Inc. stock is up 56.07% since 30 days ago. The next earnings date is Nov 5, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.36% of the previous 10 October’s closed higher than September. In the last 6 Unusual Options Trades, there were 1 PUT, 5 CALLs. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

28 Sep 14:28	18 Dec, 2026	7.50	PUT	300	9
28 Sep 16:22	18 Dec, 2026	5.00	CALL	200	381
28 Sep 16:22	18 Dec, 2026	5.00	CALL	200	381
28 Sep 17:10	20 Nov, 2026	5.00	CALL	500	0
28 Sep 17:13	20 Nov, 2026	5.00	CALL	420	0
28 Sep 17:20	20 Nov, 2026	5.00	CALL	476	0

Advanced Data Unlock

Benzinga Newsdesk

Wed Aug 5, 2026

Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M Estimate

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 24 percent increase over losses of $(0.25) per share from
Benzinga Newsdesk

Wed Aug 5, 2026

Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.176M Est

Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 million to $120.000 million-$125.000 million vs $122.176 million estimate.
Benzinga Newsdesk

Tue Jun 16, 2026

Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $6 to $6.5.
Benzinga Newsdesk

Mon Jun 15, 2026

Lifecore Biomedical Announced It Has Signed A New Agreement With A Global Pharmaceutical Company
Benzinga Newsdesk

Tue Jun 2, 2026

Lifecore Biomedical Signs Manufacturing Services Agreement To Perform Process Development And Technical Transfer Services In Support Of Anticipated Commercial Manufacturing Upon Regulatory Approval

-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product ---- Sixth Addition to Late-Stage Pipeline in Seven Months --CHASKA, Minn., June 02, 2026 (GLOBE
Benzinga Insights

Wed May 6, 2026

Earnings Scheduled For May 6, 2026
Benzinga Insights

Wed May 6, 2026

Lifecore Biomedical Q1 2026 Earnings Call Transcript
Benzinga Newsdesk

Wed May 6, 2026

Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.430M Est

Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 million to $120.000 million-$125.000 million vs $122.430 million estimate.
Benzinga Newsdesk

Wed May 6, 2026

Lifecore Biomedical Q1 EPS $(0.43) Misses $(0.24) Estimate, Sales $23.193M Miss $26.501M Estimate

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.24) by 79.17 percent. This is a 18.87 percent increase over losses of $(0.53) per share
Benzinga Newsdesk

Wed Apr 29, 2026

Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $5.5 to $6.

Barrington Research

Tue Sep 29, 18:03

hold

downgrade
William Blair

Mon Sep 28, 20:21

hold

downgrade